Tempus and Stemline Therapeutics Announce Collaboration to Implement Tempus Next to Support Patients with Metastatic Breast Cancer
“We are thrilled to enter this collaboration with Tempus, a leader in leveraging AI to advance precision medicine and patient care. ESR1 mutations can stop tumors from responding to standard endocrine therapy, in turn causing the cancer to progress. With an approved treatment that targets these mutations, the identification of ESR1 is a critical step in customizing care for patients with ER+, HER2- metastatic breast cancer,” said Yasir Nagarwala, Senior Vice President, Medical Affairs, Stemline Therapeutics, Inc. “At Menarini Stemline, we are focused on bringing transformational therapies to patients living with cancer, and by partnering with companies like Tempus, we are able to help physicians understand when testing for an ESR1 mutation may be appropriate.”
Share:
More News
“Between 2017 and 2023, the socioeconomic burden of HER2-positive breast cancer in ten major economies was nearly $590 billion, projected to increase to nearly $1,000 billion by 2032,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development. “At-home treatment may help alleviate the pressure
Richard Saynor, CEO of Sandoz, said: “The global burden of cancer continues to grow and the potential to address unmet patient needs has never been greater. This agreement offers us the chance to reach many more millions of patients, while helping to drive the long-term sustainability of healthcare systems.”
“Beyond the second-line monotherapy opportunity, we and our partners at Pfizer have removed plans for a Phase 3 first-line combination trial with atirmociclib, as well as the planned Phase 3 second-line combination trial with a CDK4/6 inhibitor, from our joint development plan,” continued Dr. Houston. “This decision was made following
“The interim PFS analysis results demonstrated that, compared to the current standard treatment, KN026 in combination with chemotherapy significantly improved PFS, reduced the risk of disease progression or death, and showed a trend toward OS benefit. Detailed data from this study will be presented at an upcoming international academic conference.”
